ASH 2023 | Selinexor-based triplet regimens in multiple myeloma
Gary Schiller, MD, University of California, Los Angeles, CA, discusses the possibility of using selinexor-based triplet regimens (for example, selinexor with dexamethasone and carfilzomib) for the treatment of heavily pretreated patients with multiple myeloma (MM) who have previously experienced treatment failure with anti-CD38 monoclonal antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Stemline Therapeutics, Astellas Pharma, Sanofi, Kite, AbbVie, Jazz Pharmaceuticals, Incyte, Bristol Myers Squibb, Karyopharm Therapeutics; Research Funding: Geron, REGiMMUNE, Samus Therapeutics, Takeda, Mateon Therapeutics, Sangamo Bioscience, Deciphera, FORMA Therapeutics, Astellas Pharma, Sanofi, Sellas Life Sciences, Kite, Delta-Fly Pharma, Daiichi Sankyo, AbbVie, Precog, Jazz Pharmaceuticals, Celgene, Novartis, Incyte, Stemline Therapeutics, Trovagene, Bristol Myers Squibb, Amgen, Tolero Pharmaceuticals, Pfizer, Onconova Therapeutics, Actinium Pharmaceuticals, Karyopharm Therapeutics, Genentech/Roche, Gamida Cell, Fujifilm, Constellation Pharmaceuticals, Celator, Arog, Actuate Therapeutics, Agios, ElevateBio, Ono Pharmaceutical, AVM Biotechnology, Syros Pharmaceuticals, Kronos Bio; Consultancy: Astellas Pharma, AbbVie, Jazz Pharmaceuticals, Celgene, Novartis, Incyte, Agios, Ono Pharmaceutical; Current equity holder in publicly-traded company: Bristol Myers Squibb, Amgen, Johnson & Johnson.
